Patient’ and social aspects related to complementary mistletoe therapy in patients with breast cancer: A systematic review commissioned by the German agency for Health Technology Assessment
European Journal of Oncology Nursing · 2023
DOI: 10.1016/j.ejon.2023.102338 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Oncology Nursing, 2023. Verfasst von Caroline Steigenberger und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Heal…. Hauptthemen laut MEDLINE: Mistletoe, Antineoplastic Agents, Phytogenic, Breast Neoplasms, Viscum album. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Bundesinstitut für Arzneimittel und Medizinprodukte.
Abstract (Originalsprache)
PURPOSE: To mitigate side effects of conventional cancer care and improve quality of life, many patients with breast cancer in German-speaking countries opt for mistletoe therapy in addition to standard treatment. To understand the value for users, we evaluated the domain "Patient and Social aspects" in a health technology assessment on complementary mistletoe therapy in patients with breast cancer. METHODS: A systematic review was conducted according to PRISMA guidelines. Fifteen electronic databases and the internet were searched. Qualitative studies were analyzed using qualitative content analysis; quantitative studies were systematically summarized in evidence tables. RESULTS: Seventeen studies out of 1203 screened publications with 4765 patients and 869 healthcare professionals were included in the review. The median proportion of patients using mistletoe therapy was 26.7% (range: 7.3-46.3%). Predictors for use were younger age and higher educational level. Main reasons for patients' use of mistletoe therapy were to leave nothing untried and to be actively involved in the treatment process. Reasons against use were related to a lack of knowledge or uncertainty regarding effectiveness and safety. Physicians mainly aimed to support the patient's physical condition as main reason for use and a lack of resources and knowledge as main reason against use. CONCLUSION: Mistletoe therapy was commonly used in the treatment of breast cancer despite a lack of scientific knowledge among patients and physicians. Transparent communication on motivation for use and its potential effect enables realistic expectations. Relatively small samples of mistletoe therapy users limit the representativeness and validity of our results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL - University for Health Sciences…
Förderung
- Bundesinstitut für Arzneimittel und Medizinprodukte
Zitieren
APA
Steigenberger, C., Schnell-Inderst, P., Flatscher-Thöni, M., Plank, L. M., & Siebert, U. (2023). Patient’ and social aspects related to complementary mistletoe therapy in patients with breast cancer: A systematic review commissioned by the German agency for Health Technology Assessment. European Journal of Oncology Nursing. https://doi.org/10.1016/j.ejon.2023.102338
Vancouver
Steigenberger C, Schnell-Inderst P, Flatscher-Thöni M, Plank LM, Siebert U. Patient’ and social aspects related to complementary mistletoe therapy in patients with breast cancer: A systematic review commissioned by the German agency for Health Technology Assessment. European Journal of Oncology Nursing. 2023. doi:10.1016/j.ejon.2023.102338
BibTeX
@article{Steigenberger2023,
author = {Steigenberger, Caroline and Schnell-Inderst, Petra and Flatscher-Thöni, Magdalena and Plank, Lisa-Maria and Siebert, Uwe},
title = {Patient’ and social aspects related to complementary mistletoe therapy in patients with breast cancer: A systematic review commissioned by the German agency for Health Technology Assessment},
journal = {European Journal of Oncology Nursing},
year = {2023},
doi = {10.1016/j.ejon.2023.102338}
}
EUVIMED